James N. Topper Buys 4,005 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) Stock

NewAmsterdam Pharma (NASDAQ:NAMS) Director James N. Topper bought 4,005 shares of the firm’s stock in a transaction dated Tuesday, March 4th. The shares were acquired at an average price of $21.02 per share, with a total value of $84,185.10. Following the completion of the transaction, the director now owns 3,012,434 shares of the company’s stock, valued at approximately $63,321,362.68. The trade was a 0.13 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

NewAmsterdam Pharma Stock Performance

Shares of NewAmsterdam Pharma stock opened at $23.80 on Friday. The company has a market capitalization of $2.20 billion, a PE ratio of -9.15 and a beta of -0.04. The company has a 50-day simple moving average of $22.24 and a two-hundred day simple moving average of $20.43. NewAmsterdam Pharma has a one year low of $15.19 and a one year high of $27.29.

NewAmsterdam Pharma (NASDAQ:NAMS) last announced its earnings results on Wednesday, February 26th. The company reported ($0.95) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.47). The business had revenue of $12.77 million for the quarter, compared to analyst estimates of $3.30 million. On average, equities analysts predict that NewAmsterdam Pharma will post -1.75 earnings per share for the current fiscal year.

Analyst Ratings Changes

NAMS has been the subject of several recent research reports. Royal Bank of Canada restated an “outperform” rating and issued a $40.00 price objective on shares of NewAmsterdam Pharma in a report on Friday, January 24th. Needham & Company LLC decreased their price objective on NewAmsterdam Pharma from $46.00 to $42.00 and set a “buy” rating for the company in a report on Thursday, February 27th. Scotiabank lifted their price objective on NewAmsterdam Pharma from $47.00 to $52.00 and gave the company a “sector outperform” rating in a report on Thursday, February 27th. Finally, HC Wainwright restated a “buy” rating and issued a $48.00 price objective on shares of NewAmsterdam Pharma in a report on Tuesday, January 14th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, NewAmsterdam Pharma presently has an average rating of “Buy” and a consensus target price of $43.80.

Hedge Funds Weigh In On NewAmsterdam Pharma

A number of large investors have recently added to or reduced their stakes in the company. GF Fund Management CO. LTD. purchased a new stake in shares of NewAmsterdam Pharma during the fourth quarter worth about $50,000. National Bank of Canada FI purchased a new stake in shares of NewAmsterdam Pharma during the fourth quarter worth about $51,000. Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of NewAmsterdam Pharma during the fourth quarter worth about $80,000. Quarry LP grew its stake in shares of NewAmsterdam Pharma by 2,469.2% during the third quarter. Quarry LP now owns 6,500 shares of the company’s stock worth $108,000 after acquiring an additional 6,247 shares during the last quarter. Finally, Barclays PLC boosted its position in NewAmsterdam Pharma by 1,813.4% in the third quarter. Barclays PLC now owns 7,596 shares of the company’s stock valued at $126,000 after buying an additional 7,199 shares during the last quarter. 89.89% of the stock is currently owned by institutional investors.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.